JP5800016B2 - トラマドールとコキシブとの共結晶の医薬品組成物 - Google Patents

トラマドールとコキシブとの共結晶の医薬品組成物 Download PDF

Info

Publication number
JP5800016B2
JP5800016B2 JP2013512793A JP2013512793A JP5800016B2 JP 5800016 B2 JP5800016 B2 JP 5800016B2 JP 2013512793 A JP2013512793 A JP 2013512793A JP 2013512793 A JP2013512793 A JP 2013512793A JP 5800016 B2 JP5800016 B2 JP 5800016B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
celecoxib
pain
tramadol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013512793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013530952A5 (enExample
JP2013530952A (ja
Inventor
ランザーニ,ルイス ソレール
ランザーニ,ルイス ソレール
アルデア,アルベルト ファリヴェネ
アルデア,アルベルト ファリヴェネ
Original Assignee
ラボラトリオス デル ドクトル エステーヴ,エセ.ア.
ラボラトリオス デル ドクトル エステーヴ,エセ.ア.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラボラトリオス デル ドクトル エステーヴ,エセ.ア., ラボラトリオス デル ドクトル エステーヴ,エセ.ア. filed Critical ラボラトリオス デル ドクトル エステーヴ,エセ.ア.
Publication of JP2013530952A publication Critical patent/JP2013530952A/ja
Publication of JP2013530952A5 publication Critical patent/JP2013530952A5/ja
Application granted granted Critical
Publication of JP5800016B2 publication Critical patent/JP5800016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2013512793A 2010-06-04 2011-06-03 トラマドールとコキシブとの共結晶の医薬品組成物 Active JP5800016B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10384002.1 2010-06-04
EP10384002A EP2392319A1 (en) 2010-06-04 2010-06-04 Pharmaceutical compositions of co-crystals of tramadol and coxibs
PCT/EP2011/002749 WO2011151080A1 (en) 2010-06-04 2011-06-03 Pharmaceutical compositions of co-crystals of tramadol and coxibs

Publications (3)

Publication Number Publication Date
JP2013530952A JP2013530952A (ja) 2013-08-01
JP2013530952A5 JP2013530952A5 (enExample) 2015-02-19
JP5800016B2 true JP5800016B2 (ja) 2015-10-28

Family

ID=42358396

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013512793A Active JP5800016B2 (ja) 2010-06-04 2011-06-03 トラマドールとコキシブとの共結晶の医薬品組成物

Country Status (33)

Country Link
US (1) US8846744B2 (enExample)
EP (3) EP2392319A1 (enExample)
JP (1) JP5800016B2 (enExample)
KR (1) KR101556700B1 (enExample)
CN (1) CN102946871B (enExample)
AR (1) AR081774A1 (enExample)
AU (1) AU2011260608B2 (enExample)
CA (1) CA2798090C (enExample)
CO (1) CO6660469A2 (enExample)
CY (1) CY1118813T1 (enExample)
DK (1) DK2575778T3 (enExample)
EC (1) ECSP13012368A (enExample)
ES (1) ES2622192T3 (enExample)
HR (1) HRP20170594T1 (enExample)
HU (1) HUE033999T2 (enExample)
IL (1) IL222731A (enExample)
LT (1) LT2575778T (enExample)
MX (1) MX351507B (enExample)
MY (1) MY156859A (enExample)
NZ (1) NZ603457A (enExample)
PH (1) PH12012502171A1 (enExample)
PL (1) PL2575778T3 (enExample)
PT (1) PT2575778T (enExample)
RS (1) RS55878B1 (enExample)
RU (1) RU2567843C2 (enExample)
SG (1) SG185385A1 (enExample)
SI (1) SI2575778T1 (enExample)
SM (1) SMT201700261T1 (enExample)
TN (1) TN2012000515A1 (enExample)
TW (1) TWI508722B (enExample)
UA (1) UA109661C2 (enExample)
WO (1) WO2011151080A1 (enExample)
ZA (1) ZA201208767B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177215A1 (en) * 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
EP2311446A1 (en) * 2009-10-16 2011-04-20 Laboratorios Del. Dr. Esteve, S.A. Compositions comprising Tramadol and Celecoxib in the treatment of pain
US9138425B2 (en) 2013-03-12 2015-09-22 Patheon Inc. Drug delivery system to increase bioavailability
CA2947528C (en) 2014-05-01 2023-09-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
RU2016147008A (ru) * 2014-05-01 2018-06-04 Сан Фармасьютикал Индастриз Лимитед Жидкие композиции метформина с пролонгированным высвобождением
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
BR112017001968A2 (pt) 2014-07-30 2017-11-21 Sun Pharmaceutical Ind Ltd embalagem de duas câmaras para uma composição farmacêutica líquida oral de múltiplas doses
WO2016046693A1 (en) * 2014-09-25 2016-03-31 Nathwani Sandeep Vinodkumar A co-processed pharmaceutical excipient
CN104276960B (zh) * 2014-09-26 2016-09-28 安徽省逸欣铭医药科技有限公司 盐酸他喷他多和塞来昔布共晶及其组合物和制备方法
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
WO2018031577A1 (en) * 2016-08-09 2018-02-15 Autotelic Llc Fixed dose combination for pain relief without edema
DE102016012746A1 (de) 2016-10-25 2018-04-26 WindplusSonne GmbH Vorprodukte zur Herstellung von porösen, mineralischen Leichtbaumaterialien, Verfahren zur Herstellung von porösen, mineralischen Leichtbaumaterialien und ihre Verwendung
JP2020510625A (ja) * 2016-12-14 2020-04-09 ナンジェネックス ナノテクノロジー インコーポレーテッドNangenex Nanotechnology Incorporated セレコキシブを含有する医薬組成物
CN107595792A (zh) * 2017-11-06 2018-01-19 刘丽 一种盐酸他喷他多塞来昔布片剂及其制备方法
CN110101673A (zh) * 2019-05-07 2019-08-09 安徽金太阳生化药业有限公司 一种盐酸曲马多分散片的制备方法
CA3137381A1 (en) * 2019-05-14 2020-11-19 Esteve Pharmaceuticals, S.A. Use of co-crystals of tramadol and celecoxib for treating pain while reducing the abuse liability of tramadol
CN112007024A (zh) * 2019-05-28 2020-12-01 江苏恒瑞医药股份有限公司 艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途
SI4337169T1 (sl) * 2021-05-11 2026-05-29 Cingulate Therapeutics LLC Trimodalna tableta s časovno nastavljivim pulzirnim sproščanjem
CN115251264B (zh) * 2022-08-05 2023-11-21 齐鲁工业大学 含桑叶提取物的共结晶粉末功能性饮料及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513924A (en) * 1999-03-01 2001-09-28 Ortho Mcneil Pharm Inc Composition comprising a tramadol material and a selective cox-2 inhibitor drug
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
PT1478366E (pt) * 2002-02-19 2009-03-10 Adcock Ingram Ltd Combinações farmacêuticas de meloxicam, fosfato de codeína e paracetamol
JP2005154334A (ja) * 2003-11-25 2005-06-16 Toa Yakuhin Kk アズレンスルホン酸塩水溶液剤
DE102006044694A1 (de) * 2006-09-22 2008-03-27 Krewel Meuselbach Gmbh Perorale feste Schmerzmittelzubereitung
WO2008085674A1 (en) * 2007-01-04 2008-07-17 Transform Pharmaceuticals, Inc. Pharmaceutical compositions comprising celecoxib co-crystals
CN101254180B (zh) * 2008-03-28 2010-11-10 辽宁正鑫药物研究有限公司 一种内容物为半固体组合物的尼莫地平胶囊剂及制备方法
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs

Also Published As

Publication number Publication date
US20130109659A1 (en) 2013-05-02
EP2575778B1 (en) 2017-01-18
RS55878B1 (sr) 2017-08-31
IL222731A (en) 2016-05-31
DK2575778T3 (en) 2017-04-18
KR20130093015A (ko) 2013-08-21
US8846744B2 (en) 2014-09-30
TW201143760A (en) 2011-12-16
MX2012014087A (es) 2013-02-27
HUE033999T2 (en) 2018-01-29
CA2798090C (en) 2017-02-28
MX351507B (es) 2017-10-18
ECSP13012368A (es) 2013-01-31
EP2392319A1 (en) 2011-12-07
AU2011260608A1 (en) 2012-11-22
CA2798090A1 (en) 2011-12-08
NZ603457A (en) 2014-10-31
IL222731A0 (en) 2012-12-31
SG185385A1 (en) 2012-12-28
SMT201700261T1 (it) 2017-07-18
AR081774A1 (es) 2012-10-17
RU2567843C2 (ru) 2015-11-10
PL2575778T3 (pl) 2017-09-29
PT2575778T (pt) 2017-04-21
CY1118813T1 (el) 2018-03-07
CO6660469A2 (es) 2013-04-30
ES2622192T3 (es) 2017-07-05
MY156859A (en) 2016-04-15
LT2575778T (lt) 2017-04-10
TWI508722B (zh) 2015-11-21
AU2011260608B2 (en) 2015-05-07
SI2575778T1 (sl) 2017-07-31
KR101556700B1 (ko) 2015-10-01
UA109661C2 (uk) 2015-09-25
EP3158994A1 (en) 2017-04-26
TN2012000515A1 (en) 2014-04-01
WO2011151080A1 (en) 2011-12-08
CN102946871B (zh) 2019-03-08
RU2012157256A (ru) 2014-07-20
PH12012502171A1 (en) 2016-02-24
JP2013530952A (ja) 2013-08-01
CN102946871A (zh) 2013-02-27
ZA201208767B (en) 2013-07-31
BR112012030704A2 (pt) 2016-09-13
EP2575778A1 (en) 2013-04-10
HRP20170594T1 (hr) 2017-06-16

Similar Documents

Publication Publication Date Title
CA2798090C (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
RU2710370C2 (ru) Фармацевтические композиции, содержащие целекоксиб и трамадол
KR20200088382A (ko) 방출 제어 제제
RU2662562C2 (ru) Композиция в форме таблеток, содержащая гидрохлорид цинакалцета
CN117529310A (zh) 微粒化的索拉贝隆的组合物及其使用方法
WO2013169218A1 (en) Pharmaceutical compositions of s-etodolac
KR20100064015A (ko) 제어 방출성 아세클로페낙을 함유하는 경구 제제의 조성물 및 그의 제조방법
HK1180981A (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
HK1180982B (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
HK1180982A (en) Pharmaceutical compositions of co-crystals of tramadol and coxibs
CN105407882A (zh) 包含呈阿戈美拉汀与有机酸的共晶体形式的阿戈美拉汀的药物制剂
BR112012030704B1 (pt) Composição farmacêutica de cocristais e processo para sua produção
JP2016098230A5 (enExample)
JP2016098230A (ja) 末梢血管疾患を有する患者における間欠跛行の症状を軽減するために用いられるキノリノン誘導体シロスタゾールの新規製剤
EP2934485A1 (en) Tablet composition comprising cinacalcet hydrochloride
JP2026502913A (ja) ルキソリチニブの多重放出制御錠剤組成物及びその製造方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141225

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20141225

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150728

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150810

R150 Certificate of patent or registration of utility model

Ref document number: 5800016

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250